The company has not filed an annual or quarterly report since its Q2 FY2019 10-Q, filed Aug 6, 2019. Its latest SEC filing is a SC 13G/A from Feb 13, 2020.
10-Q for Q2 FY2019, filed Aug 6, 2019
The sections below describe the company as of the FY2018 annual report.
Develops antibody medicines for migraine prevention for physicians and patients, led by eptinezumab, and is developing another migraine-treatment candidate.
10-K for FY2018, filed Feb 25, 2019We are a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the…View ↗
We are focusing our resources and development efforts principally on eptinezumab (ALD403), our solely-owned lead investigational product…View ↗
Our product candidate pipeline also includes ALD1910, a high specificity, high affinity neutralizing monoclonal antibody with reactivity to…View ↗
Headache specialists were Alder's planned U.S. market for eptinezumab, which it intended to commercialize itself if approved; it was reviewing partnerships for markets outside the United States. Alder also licensed clazakizumab rights to Vitaeris.
10-K for FY2018, filed Feb 25, 2019Assuming eptinezumab administered via infusion is approved by the FDA, we plan to focus our initial commercialization efforts on procedure…View ↗
We are committed to commercializing eptinezumab in the United States as a migraine prevention therapy, and are focused on capturing the…View ↗
In May 2016, we licensed the exclusive worldwide rights for clazakizumab, another product candidate internally developed by Alder, to…View ↗
10-Q for Q2 FY2019, filed Aug 6, 2019
−$58.4MView ↗
8-K, filed Oct 22, 2019
Completion of Acquisition or Disposition of Assets.View ↗
8-K, filed Sep 16, 2019
Agreement and Plan of MergerView ↗
Clazakizumab rights
The older report said Alder was seeking strategic alternatives for clazakizumab; the latest report says Alder had licensed its exclusive worldwide rights to Vitaeris.
10-K for FY2015, filed Feb 23, 2016 10-K for FY2018, filed Feb 25, 2019We are also focusing our development efforts on ALD1613, a wholly-owned therapeutic antibody which targets adrenocorticotropic hormone…View ↗
In May 2016, we licensed the exclusive worldwide rights for clazakizumab, another product candidate internally developed by Alder, to…View ↗
Pipeline focus
The older report highlighted a candidate for adrenal hyperplasia and Cushing’s disease; the latest report describes a preclinical candidate for migraine alongside eptinezumab.
10-K for FY2015, filed Feb 23, 2016 10-K for FY2018, filed Feb 25, 2019We are also focusing our development efforts on ALD1613, a wholly-owned therapeutic antibody which targets adrenocorticotropic hormone…View ↗
Competes with Amgen, Lilly, Teva, Wyeth, Johnson & Johnson, Allergan, and Biohaven
10-K for FY2018, filed Feb 25, 2019Eptinezumab, if approved, will compete with three CGRP inhibiting therapies that received FDA approval in 2018 for the preventive treatment…View ↗
Loading...
